Form 4: Immunome Inc. Director Sells Shares Under 10b5-1 Plan

Immunome Inc. Director Isaac Barchas reported the sale of common stock totaling 200,000 shares through Rule 10b5-1 trading plans, with transactions occurring on June 30 and July 2, 2026.

Summary

• Director Isaac Barchas reported sales of Immunome Inc. common stock on June 30 and July 2, 2026.
• These sales were executed automatically under pre-established Rule 10b5-1 trading plans.
• A total of 200,000 shares were sold across these transactions.
• The sales involved entities managed by Barchas, including ABHMC II LLC and Arsenal Bridge Venture II-B LLC.
• Barchas disclaims beneficial ownership of the sold shares beyond his pecuniary interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details routine share sales by a director under a pre-established 10b5-1 plan, which is a standard compliance mechanism.

Negatives

• Director Isaac Barchas sold a significant number of shares (200,000) from his holdings.
• The sales occurred at weighted average prices ranging from $21.12 to $23.33 per share.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing.

Management Comments

• The reported sale of these shares occurred automatically pursuant to Rule 10b5-1 trading plans adopted by ABHMC II LLC ("ABHMC") and Arsenal Bridge Venture II-B LLC ("ABV II-B"), each on March 31, 2026.
• The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Reporting Person is the beneficial owner of such shares.

Industry Context

StockSavvy.ai notes that Form 4 filings, particularly those involving Rule 10b5-1 plans, are routine disclosures for insiders. While sales can sometimes signal a lack of confidence, the use of a 10b5-1 plan indicates a pre-arranged selling strategy, mitigating immediate concerns about market timing.

Stakeholder Impact

• Shareholders: The sale of shares by a director may be perceived negatively, but the use of a 10b5-1 plan suggests a pre-determined strategy rather than a reaction to non-public information.
• Management: Reinforces the company's adherence to regulatory requirements for insider transactions.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Stock Sale, Immunome Inc., IMNM, Director Transaction, Beneficial Ownership